Long-Term Effectiveness of a Home-Based Pulmonary Rehabilitation in Older People with Chronic Obstructive Pulmonary Disease: A Retrospective Study

Sarah Gephine1,2, Olivier Le Rouzic3,4, François Machuron5, Benoit Wallaert1, Cécile Chenivesse3,4, Didier Saey2, François Maltais2, Patrick Mucci1, Jean-Marie Grosbois6

1Univ. Lille, Univ. Artois, Univ. Littoral Côte d’Opale, ULR 7369 - URePSSS - Unité de Recherche Pluridisciplinaire Sport Santé Société, Lille F-59000, France; 2Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, Canada; 3CHU Lille, Service de Pneumologie et Immuno-Allergologie, Centre de Référence Constitué des Maladies Pulmonaires Rares, Lille F-59000, France; 4Univ. Lille, Lille F-59000, France; 5Department of Biostatistics, Univ. Lille, CHU Lille, EA 2694 - Santé Publique: Epidemiologie et Qualité des Soins, Lille F-59000, France; 6FormAction Santé, Pérenchies, France

Background: Long-term effectiveness of pulmonary rehabilitation (PR) is still uncertain in older people with severe chronic obstructive pulmonary disease (COPD). The objective was to compare the effects of home-based PR in people with COPD above and below the age of 70 years.

Methods: In this retrospective study, 480 people with COPD were recruited and divided into those ≤70 (n=341) and those >70 years of age (n=139). All participants underwent an 8 weeks of home-based PR, consisting of a weekly supervised 90-minute home session. Six-minute step test (6MST), timed-up and go test (TUG), Hospital Anxiety and Depression Scale, and Visual Simplified Respiratory Questionnaire (VSRQ) were assessed at baseline (M0), at 2 (M2), 8 (M8), 14 (M14) months after baseline.

Results: The older group was described by fewer current smokers (p <0.001), more long-term oxygen therapy use (p = 0.024), higher prevalence of comorbidities (p<0.001), lower 6MST score and higher TUG score (p<0.001), compared to the younger group. Both groups improved every outcome at M2 compared to baseline. At M2, 88% of people ≤70 years of age and 79% of those above 70 were considered as responders in at least one evaluated parameter (p = 0.013). Both groups maintained the benefits at M14, except for the VSRQ score and the number of responders to this outcome in the older group.

Conclusion: Regardless of the age, personalized home-based PR was effective for people with COPD in the short term. Above 70 years, an ageing effect appeared on the long-term effectiveness of quality of life benefit.

Keywords: chronic obstructive pulmonary disease, exercise tolerance, pulmonary rehabilitation, quality of life, older age

Introduction

Pulmonary rehabilitation (PR) including education, motivational support, and physical activity training, is the main non-pharmacological component of chronic obstructive pulmonary disease (COPD) treatment.1 The positive effects of PR on dyspnoea, fatigue, health-related quality of life, emotional function and exercise capacity have been repeatedly confirmed.2-4 Despite the positive effects, fewer than 10% of people with COPD engage in traditional outpatient PR.5 Trying to increase the participation rate, some facilities offer personalized home-based PR. This therapeutic model seems especially appropriate for the more severe patients, for
whom travel to a facility-based programme, social deprivation, long-term oxygen therapy (LTOT), mobility limitation and frailty could constitute barriers to engage in outpatient PR.\(^6\,^7\) In COPD, home-based PR is feasible and conducts the same benefits in the short and long term, as the inpatient or outpatient programme.\(^8\,^9\)

The prevalence of COPD is increasing in people over age groups.\(^1,\) In the current context of an ageing population associated with concerns about COPD-related health costs, it seems necessary to tailored PR programmes to older people with a higher risk of severe COPD and comorbidities. Indeed, it is common for older people to suffer from heart diseases, undernutrition, alterations in cognitive function, poor functional capacity and decreased muscle function and exercise capacity.\(^12\,^13\) Because of its physiological and functional effects, PR has sometimes been considered inappropriate for older people with COPD, especially for whom at risk of chronic respiratory failure.\(^14\,^15\) Few retrospective studies have evaluated the effectiveness of PR in people with COPD over the age of 70, in comparison to their younger counterparts.\(^16\,^18\) However, none of these reported on the efficacy of home-based PR and on the long-term benefits in people with COPD above 70. Moreover, the features of home-based settings may facilitate the attendance of older people with COPD requiring LTOT\(^10\) but the effects of age combined with respiratory aid equipment on PR were never reported. The aim of this study was to determine whether being older than 70 years impacts the short- and long-term effects of a home-based PR on exercise tolerance, functional capacity and health related to the quality of life in people with COPD.

**Methods**

**Study Design and Participants**

This was a large observational study conducted in a private company offering home-based PR for people with the chronic respiratory disease living in the north of France, from January 2010 to June 2017, with retrospective data analysis performed in 2019. Participants were referred to the home-based PR by their pulmonologist who diagnosed COPD according to the Global initiative for chronic obstructive lung disease (GOLD) classification system and validated that the participants were absent of cardiovascular contraindications to exercise training. From 2010 to 2017, more than one hundred pulmonologists referred their patients to the programme. Participants were excluded from the retrospective analysis if they had dementia or poorly controlled psychiatric illness, neurological sequelae, or bone and joint diseases preventing physical activity, or if they refused during the initial visit to participate in the PR. Participants were divided into two groups: one group included individuals aged ≤70 years, and the other one, people >70 years. The cut-off of 70 years to define the older group was chosen in accordance with the World Health Organization report on ageing and health.\(^19\) The study was performed in accordance with the observational research protocol evaluation committee of the French Language Society of Pulmonology (CEPRO 2017–007), who approved the retrospective analysis. All participants signed a written informed consent prior to the start of the programme which included their approval to use the collected data for research purposes.

**Home-Based PR Programme**

All participants received a home-based PR programme tailored to each patient’s individual needs as previously described.\(^20\,^21\) Briefly, it consisted of a weekly supervised 90-minute home session, for 8 weeks. The rehabilitation team was composed of one pulmonologist, two nurses, one dietician, one physiotherapist, two adapted physical activity instructors and one sociomedical beautician. The healthcare team received the same standardized therapeutic education training. The programme included an initial educational needs assessment, endurance physical exercise training, specific daily living functional task training, strengthening and balance exercises, lower limb electrostimulation, therapeutic education, psychosocial support, and motivational communication.\(^22\) Each participant received a cycle ergometer (Domyos VM 200, Decathlon, Villeneuve-d’Ascq, France) during the 8-week programme to perform endurance training. It was initially performed by 10-minute sequences (or sometimes shorter if the participant was unable to perform it), at least 5 days per week, by trying to achieve 30–45 minutes of exercise, in one or several sessions, per day. Exercise intensity was progressively adjusted to dyspnoea symptoms in order to maintain a score between 3 and 5 on the Borg 0–10 scale. For the most unconditioned participants, for whom the initial 6-minute stepper test score was <150 strokes, the training started with two 30-minute sessions daily of quadriceps electrostimulation, 5 times a week.\(^23\,^24\)

Apart from the weekly visit of the team member who supervised the sessions, participants were expected to perform, on their own, personalized daily physical activities
and endurance exercises training the rest of the week and during the follow-up period, during which there was no visit by the PR team apart from those mandated to complete the evaluation at 8 and 14 months after PR. Patients and team members were instructed to announce all adverse events including study withdrawal for any reasons, hospitalization or death during PR and the 12-month follow-up.

Assessments

Patients were evaluated at home at the beginning (M0), at the end of the 8-week PR programme (M2), and at 8 (M8) and 14 months (M14) to conclude a full year of follow-up post PR. As previously described, the 6-minute stepper test (6MST) and the timed up-and-go test (TUG) were used to evaluate exercise tolerance and functional capacity, respectively. The psychological status and the health-related quality of life were assessed with the Hospital Anxiety and Depression (HAD) scale, and the Visual Simplified Respiratory Questionnaire (VSRQ), respectively.

In COPD, the minimal clinically important difference (MCID) of the 6MST, the TUG, the HAD-anxiety and depression scores and the VSRQ, is considered to be a change of 40 strokes, 1.5 seconds, 1.5 units and 3.4 points, respectively. Individuals were defined as a PR responder if they reached the MCID of at least one of the outcomes (6MST, TUG, anxiety, depression and VSRQ).

Finally, the burden of comorbidity was assessed using the Charlson Index calculated without adjusting for age and without including COPD in the individual’s score, as previously suggested.

Statistical Analysis

Statistical analysis was performed using SAS V9.4 (SAS Institute, Cary NC, USA) and the significance threshold was considered at 0.05. Variables were expressed as mean ± standard deviation or as frequencies and percentage, and were tested for normality. Between groups comparison for baseline variables were performed using Chi-squared test and t-test. Linear random effects mixed model was used to evaluate the changes in study outcomes over time (M2, M8, M14), considering baseline value as a covariate. Residual analyses were used to validate the models. In the case of the non-normality of residuals, the data were log-transformed. All analyses were adjusted for confounding factors (age, LTOT, heart rhythm disorders, hypertension, diabetes, high cholesterol, coronary heart disease, smoking status, weight and height).

Results

From January 2010 to June 2017, 509 people with COPD were referred to the home-based PR. Among them, 15 people refused to be contacted by the private company and another 14 participants refused to start the programme after the initial visit (Figure 1). The majority of the 480 participants included in the retrospective analysis were males, aged 64 ± 11 years and had severe COPD with cardiac comorbidity (Table 1). Over two thirds of the total group used LTOT. Among the 480 participants, 341 (71%) were ≤70 years old (mean age 59 ± 8 years), and 139 (29%) were assigned in the older group (mean age 77 ± 5 years). The older group was characterized by fewer current smokers (p < 0.001), higher predicted FEV₁ (p = 0.019), higher prevalence of comorbidities (p < 0.001), and more users of LTOT (p = 0.024) compared to the younger group (Table 1).

At baseline, the older group had lower HAD total score (p =0.038), anxiety score (p = 0.001), and 6MST performance, and higher TUG score (p<0.001) than the younger group (Table 2). Apart from the HAD score, these differences remained significant after adjustment for baseline cofounding factors. Depression and VSRQ scores were comparable between the two groups.

Withdrawals

No adverse events related to PR were observed. At M14, 97 (28%) and 47 (34%) of people in the younger and older group, respectively, had withdrawn from the study (p=0.203) (Figure 1). A total of 42 patients died during the study: 27 (8%) in the younger group and 15 (11%) in the older group (p=0.313) (Figure 1).

Outcomes Evolution and Responders Analysis

Short- and long-term effects of PR according to age are shown in Table 3 and Figure 2. The younger group showed improvements in all outcomes between baseline and M2, M8 and M14 (p<0.001). The older group improved all outcomes only between baseline and M2 (p<0.001). In this group of patients, only HAD total score, anxiety and depression scores remained improved thereafter. TUG and 6MST score were not different at M8 compared to the baseline (p= 0.399 and p=0.179, respectively), but reached again the significant level at M14. Comparison showed similar time courses for all
outcomes between younger and older individuals, even after being adjusted for baseline value and confounding factors.

The proportion of responders according to age is presented in Figure 3 and in Table S1. At M2, 88% of people under 70 years were considered as responders in at least one outcome compared to 79% of people aged >70 (p = 0.013). At M8 (72% versus 65%, p = 0.11), and M14 (66% versus 57%, p = 0.068), the proportion of responders in comparison to M2, decreased similarly in both groups. A similar percentage of responders between the two groups was observed at M2, M8 and M14, except for the VSRQ score where the younger group showed more responders (M2: 67 versus 55%, p = 0.05; M8: 64% versus 44% and M14: 62% versus 39%, p<0.01) compared to the older group.

Discussion

The main findings of this real-life study are that people with COPD requiring long-term oxygen therapy or non-invasive ventilation involving in home-based PR after the age of 70 as compared to their younger counterparts: i) similarly benefited from home PR, with the exception of health-related quality of life for which initial improvement was lost at the long term in the older ones; ii) showed similar proportions of long-term responders, up to 1 year after the programme, with the exception of health-related quality of life for which there were fewer long-term responders in the older ones; iii) showed similar prevalence of deaths and withdrawals from PR.

The older group was characterized by a smaller proportion of active smokers, had a larger proportion of individuals on LTOT, and presented more comorbidities compared to the younger group. After adjustment for these variables, people in the older group had lower anxiety scores and lower exercise tolerance and functional capacity, defined as the individual’s maximal potential to realize a functional activity in a standardized environment, compared to the younger group. COPD is frequently associated with comorbidities like cardiovascular and metabolic disorders,
Table 1 Baseline Characteristics of Participants

| Characteristics               | Total Group (n = 480) | ≤ 70 Year (n = 341) | > 70 Years (n=139) | p-value |
|-------------------------------|-----------------------|---------------------|-------------------|---------|
| Age, years                    | 64 ± 11               | 59 ± 8              | 77 ± 5            | <0.001  |
| Female, nb (%)                | 170 (35)              | 127 (37)            | 43 (31)           | 0.19    |
| BMI, kg/m² (n)                | 27 ± 8                | 27 ± 8              | 26 ± 7            | 0.35    |
| Current smokers, nb (%)       | 84 (17)               | 72 (21)             | 12 (9)            | <0.001  |
| LTOT, nb (%)                  | 319 (66)              | 216 (63)            | 103 (74)          | 0.024   |
| NIV, nb (%)                   | 163 (34)              | 125 (37)            | 38 (27)           | 0.051   |
| CPAP, nb (%)                  | 41 (8)                | 27 (8)              | 14 (10)           | 0.445   |
| No equipment, nb (%)          | 113 (23)              | 89 (26)             | 24 (17)           | 0.039   |
| Pulmonary function            |                       |                     |                   |         |
| FEV₁, % of predicted          | 39 ± 17               | 38 ± 17             | 41 ± 15           | 0.019   |
| FEV₁/FVC, %                   | 51 ± 14               | 51 ± 14             | 54 ± 13           | 0.089   |
| GOLD stage, nb (%)            |                       |                     |                   |         |
| 1                             | 4 (1)                 | 3 (1)               | 1 (1)             | 0.092   |
| 2                             | 101 (21)              | 72 (21)             | 29 (21)           |         |
| 3                             | 201 (45)              | 145 (42)            | 56 (40)           |         |
| 4                             | 174 (36)              | 121 (35)            | 53 (38)           |         |
| Comorbidities                 |                       |                     |                   |         |
| Asthma, nb (%)                | 55 (11)               | 41 (12)             | 14 (10)           | 0.54    |
| Sleep apnea, nb (%)           | 123 (26)              | 87 (25)             | 36 (26)           | 0.61    |
| Systemic hypertension, nb (%) | 193 (41)              | 114 (33)            | 79 (57)           | <0.001  |
| Cardiovascular disease, nb (%)| 275 (57)              | 160 (47)            | 115 (83)          | <0.001  |
| Diabetes, nb (%)              | 102 (21)              | 60 (18)             | 42 (30)           | 0.010   |
| Cholesterol, nb (%)           | 104 (22)              | 64 (19)             | 39 (28)           | 0.031   |
| Cancer, nb (%)                | 74 (15)               | 45 (13)             | 29 (21)           | 0.024   |
| Rheumatologic disease, nb (%) | 144 (30)              | 93 (27)             | 51 (37)           | 0.012   |

Note: Data are presented as n (%) or mean ± SD.

Abbreviations: BMI, body mass index; LTOT, long-term oxygen therapy; NIV, non-invasive ventilation; CPAP, continuous positive airway pressure; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; cardiovascular disease, included heart rhythm disorders, hypertension, heart failure and coronary heart disease; cancer, included lung, digestive, breast and prostate cancer; rheumatologic disease, included osteoarthritis and osteoporosis.

depression, osteoporosis, lung cancer, or muscle dysfunction whose prevalence is often accentuated by aging.34 To which extent these comorbidities mitigate the success of PR is controversial.35,36 Our results are in line with those demonstrating that a higher prevalence of comorbidities in older people with severe COPD does not impact the completion and effectiveness of PR, at least in the short term. Education and

Table 2 Assessments at Baseline

|                     | Total Group (n = 476) | ≤ 70 Year (n = 338) | > 70 Years (n=138) | p-value | *Adjusted p value |
|---------------------|-----------------------|---------------------|-------------------|---------|------------------|
| HAD, score          |                       |                     |                   |         |                  |
| Total               | 17.8 ± 7.7            | 18.3 ± 7.7          | 16.6 ± 7.5        | 0.038   | 0.254            |
| Depression          | 8.0 ± 4.2             | 8.0 ± 4.3           | 8.0 ± 4.2         | 0.932   | 0.664            |
| Anxiety             | 9.9 ± 4.6             | 10.3 ± 4.6          | 8.7 ± 4.5         | 0.001   | 0.016            |
| VSRQ, score         | 31.2 ± 15.3           | 30.7 ± 15.3         | 32.2 ± 15.4       | 0.372   | 0.506            |
| 6MST, strokes       | 311 ± 153             | 339 ± 153           | 226 ± 118         | <0.001  | <0.001           |
| TUG, seconds        | 11.3 ± 6.8            | 9.9 ± 6.2           | 14.6 ± 7.2        | <0.001  | <0.001           |

Notes: Data are presented as mean ± SD. *Adjusted for age, oxygen therapy, heart rhythm disorders, hypertension, diabetes, high cholesterol, coronary heart disease, smoking status, weight and height.

Abbreviations: HAD, Hospital Anxiety and Depression Scale; VSRQ, Visual Simplified Respiratory Questionnaire; 6MST, 6-minute step; TUG, timed up-and-go test.
self-management sessions are important to induce a change in appropriate behaviours during PR.37
Therapeutic education about comorbidities and their treatment played a leading role during our 8-week home-based programme.

People with COPD benefit to a similar extent from an inpatient, outpatient or home-based PR,38 regardless of the severity of the disease,10 the socioeconomic status,21 or gender; these benefits also persist on the long-term follow-up.20 Because of the physiological effects of ageing and comorbidities, it has been suggested that PR may not be adapted to older patients.14,39 Our results demonstrated that regardless of the age, one weekly individualized home PR session associated with self-monitored home exercises during 8-week induced short-term benefits on exercise tolerance, functional capacity, health-related quality of life, anxiety and depression. These results are thus in agreement with previous work also conducted in older people with COPD showing the benefits of 6 to 8 weeks of outpatient PR on all these outcomes.18,39 The originality of our study was to evaluate the benefits of a home-based PR in people with severe COPD receiving mostly long-term oxygen therapy and/or non-invasive ventilation. Only a few studies have been reported in this specific population,10,40 but collectively these studies and our highlight that older people with chronic respiratory failure should be considered an appropriate candidate for PR.

We opted to complete all evaluations at home; as a result, we chose the 6MST to evaluate exercise tolerance. In addition to the improvement of the 6MST performance, more than half of our participants were considered as PR responders to the 6MST, in the short and long term. The 6MST baseline score was significantly lower in the older than in the younger group, which is in line with the previous observation of a mean score fewer than 250 strokes in older people with COPD and CRF.10

The concomitant occurrence of ageing, LTOT and cardiac comorbidities promote the adoption of a sedentary lifestyle, sarcopenia and exercise intolerance in the older people. Moreover, COPD and LTOT are risk factors for fall.41 As such, because it includes various functional components essential for independent living, the TUG test is recommended as a routine screening evaluation for falls and mobility in geriatric populations42 and a cut-off value of 11 seconds is suggested to detect people at risk of falling in COPD.43 With a TUG baseline score of 15 seconds, the older group was significantly at risk of falling. Despite these baseline characteristics, the older group improved the 6MST and the TUG to the same extent as the younger group. These favorable results could be related to the nature of the home-based programme which adapted individualized daily physical activities for the most unconditioned people using lower limb electrostimulation, shorter endurance physical exercise, light muscle strengthening and balance. Together with the functional improvements, a large proportion of participants in both groups achieved clinically important improvements in VSRQ (60%) and HAD (40%) scores after the home PR, compared to less than 30% in the literature.18 The best strategy to maintain the initial effects of PR on a longer-term basis is still uncertain.44,45 Katsura et al showed that older people could maintain PR benefits 1 year after an inpatient programme composed of individual daily sessions for 2 weeks, but the study sample size was small and the exercise tolerance improvement was low (<10%).46

Table 3 Changes of the Outcomes in the Short and Long Term After PR According to Age

| HAD, Score | ≤ 70 Year | > 70 Years |
|------------|-----------|------------|
|            | M2.       | M8.        | M14.       | M2.       | M8.        | M14.       |
| Total      | 15.0 ± 7.3*** | 13.9 ± 7.6*** | 14.3 ± 7.7*** | 13.6 ± 7.1*** | 12.7 ± 7.2*** | 13.2 ± 7.6*** |
| Depression | 6.3 ± 4.2*** | 5.7 ± 4.1*** | 5.8 ± 4.4*** | 6.0 ± 3.9*** | 5.9 ± 3.7*** | 6.2 ± 4.2*** |
| Anxiety    | 8.8 ± 4.1*** | 8.3 ± 4.5*** | 8.4 ± 4.6*** | 7.6 ± 4.1*** | 6.9 ± 4.5*** | 7.1 ± 4.5*** |
| VSRQ, score| 39.7 ± 16.1*** | 40.5 ± 16.9*** | 39.9 ± 16.6*** | 37.8 ± 15.8*** | 35.7 ± 14.3*** | 34.8 ± 13.4*** |
| 6MST, strokes| 406 ± 165*** | 407 ± 182*** | 432 ± 186*** | 301 ± 135*** | 265 ± 150 | 325 ± 140*** |
| TUG, seconds | 8.6 ± 6.3*** | 8.9 ± 4.8*** | 8.4 ± 4.2*** | 13.3 ± 8.2*** | 13.4 ± 6.7 | 12.6 ± 5.5*** |

Notes: Data are presented as mean ± SD. *p<0.01 and ***p<0.001 outcomes significantly improved by comparison with baseline. Data lost across the time were taking into account by the linear random effects mixed model used.

Abbreviations: HAD, Hospital Anxiety and Depression Scale; VSRQ, Visual Simplified Respiratory Questionnaire; 6MST, 6-minute stepper test; TUG, timed up-and-go test.
Long-term follow-up following PR is often poorly documented, with an average of less than 50% of participants evaluated 1 year after the PR. In the present study, more than two thirds of the participants were evaluated at 1 year, regardless of the age, suggesting that older age does not specifically impact PR attendance. Eight weeks of home-based intervention follows by one visit 6 months after (M8), seems to facilitate the adherence and maintaining PR benefits up to 1 year after the programme. However, the medium-term maintenance of exercise tolerance and functional capacity and the long-term maintenance of the health-related quality of life was more challenging in the older group. It is possible that offering a closer follow-up (visits at 3, 6, 9 and 12 months after PR, for example) would help older people to better maintain the benefits of PR.

The monocentric, observational, non-randomized, and retrospective nature of this study may limit the generalizability of the results. However, data were collected systematically and consistently as an integral part of the home-based PR including a large number of participants in a “real life” setting. The programme was funded by oxygen companies allowing for even the most in-need people to benefit. Also, the intervention was conducted according to a well-defined protocol and always by the same trained team. By improving external validity and establishment in usual care, real-life studies such as the present one are useful to complement the results of traditional randomized controlled trial.

In conclusion, the present retrospective study demonstrated that, although being older than 70 years is associated with reduced exercise tolerance and functional capacity and higher prevalence of comorbidities and long-term oxygen therapy use, this does not prevent people with
COPD from deriving short- and long-term benefits from home-based PR.

Acknowledgments
Home-based PR was financially supported by Adair, Aeris Santé, Bastide, France Oxygène, Homeperf, LVL, Medopale, NorOx, Santélys, SOS Oxygène, Sysmed, VitalAire, and ARS Hauts-de-France. Sarah Gephine was supported by doctoral salary from the University of Lille. We also thank the members of the rehabilitation team: Sophie Duriez, Mathieu Grosbois, Marjorie Lambinet, Gaelle Tywoniuik, Florence Urbain, Valentine Opsomer, and Virginie Wauquier.

Disclosure
Jean-Marie Grosbois reports home-based PR was financially supported by Adair, Aeris Santé, Bastide, France Oxygène, Homeperf, LVL, Medopale, NorOx, Santélys, SOS Oxygène, Sysmed, VitalAire, and ARS Hauts-de-France. The funders played no role in the design, conduct or reporting of this study. OLR reports personal fees and/or non-financial support from AstraZeneca, Boehringer Ingelheim, Chiesi, Lilly and Novartis, non-financial support from GlaxoSmithKline, Mayoli, MSD, Pfizer, PulmonX, Santelys association, Vertex, Vitalaire and Zambon, outside the submitted work. JMG reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, and Roche, non-financial support unrelated to the submitted work from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKlein, Novartis, Vitalaire, and Roche, and received financial support from Adair, Aeris Santé, Bastide, France Oxygène, Homeperf, LVL, Medopale, NorOx, Santélys, SOS Oxygène, Sysmed, VitalAire, and ARS Hauts-de-France for the home-based PR programme. The funders played no role in the design, conduct or reporting of this study. BW reports personal fees and non-financial support unrelated to the submitted work from Boehringer Ingelheim, Vitalaire, and Roche. CC reports personal fees and non-financial support unrelated to the submitted work from ALK-Abello, AstraZeneca, Boehringer Ingelheim, Chiesi,
GlaxoSmithKlein, MEDA Pharma, Medexact, Novartis, Pierre Fabre, Pfizer, Roche, Sanofi, Santélys, and TEVA. The aforementioned authors report no other potential conflicts of interest for this work. None of the other authors have any conflict of interest to disclose.

References

1. Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006;173(12):1390–1413. doi:10.1164/rccm.200508-1211ST

2. Spruit MA, Singh SJ, Garvey C. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188(8):e13–e64. doi:10.1164/rccm.201309-1634ST

3. Puhan MA, Lareau SC. Evidence-based outcomes from pulmonary rehabilitation in the chronic obstructive pulmonary disease patient. Clin Chest Med. 2014;35(2):295–301. doi:10.1016/j.ccm.2014.02.001

4. McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Laccase Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;(2):CD003793.

5. Rochester CL, Vogiatzis I, Holland AE, et al. An official american thoracic society/european respiratory society policy statement: enhancing implementation, use, and delivery of pulmonary rehabilitation. Am J Respir Crit Care Med. 2015;192(11):1373–1386. doi:10.1164/rccm.201510-1966ST

6. Keating A, Lee A, Holland AE. What prevents people with chronic obstructive pulmonary disease from attending pulmonary rehabilitation? A systematic review. Chron Respir Dis. 2011;8(2):89–99. doi:10.1177/1749997X11393756

7. Hayton C, Clark A, Olive S, et al. Barriers to pulmonary rehabilitation: characteristics that predict patient attendance and adherence. Respir Med. 2013;107(3):401–407. doi:10.1016/j.rmed.2012.11.016

8. Malais F, Bourbeau J, Shapiro S, et al. Effects of home-based pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2008;149(12):869–878. doi:10.7326/0003-4819-149-12-200812160-00006

9. Holland AE, Mahal A, Hill CJ, et al. Home-based rehabilitation for COPD using minimal resources: a randomised, controlled equivalence trial. Thorax. 2017;72(1):57–65.

10. Coquart JB, Le Rouzic O, Racil G, Wallaert B, Grosbois JM. Real-life feasibility and effectiveness of home-based pulmonary rehabilitation in chronic obstructive pulmonary disease requiring medical equipment. Int J Chron Obstruct Pulmon Dis. 2017;12:3549–3556. doi:10.2147/COPD.S150827

11. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28(3):523–532. doi:10.1183/09031936.06.00124605

12. Keller K, Engelhardt M. Strength and muscle mass loss with aging process. Age and strength loss. Muscles Ligaments Tendons J. 2013;3(4):346–350. doi:10.3298/jmlt.04.2013.17

13. Harada CN, Natelson Love MC, Triebel KL. Normal cognitive aging. Clin Geriatr Med. 2013;29(4):737–742. doi:10.1016/j.cger.2013.07.002

14. Corhay JL, Nguyen D, Duyssinx B, et al. Should we exclude elderly patients with chronic obstructive pulmonary disease from a long-term ambulatory pulmonary rehabilitation programme? J Rehabil Med. 2012;44:466–472. doi:10.2340/16501977-0973

15. Barnes PJ. Pulmonary diseases and ageing. Säckel Biochem. 2019;91:45–74.

16. Couser JJ, Guthmann R, Hamadeh MA, Kane CS. Pulmonary rehabilitation improves exercise capacity in older elderly patients with COPD. Chest. 1995;107(5):730–734. doi:10.1378/chest.107.3.730

17. Baltzan MA, Kamel H, Alter A, Rotapel M, Wolkove N. Pulmonary rehabilitation improves functional capacity in patients 80 years of age or older. Can Respir J. 2004;11(6):407–413. doi:10.1155/2004/632153

18. Bennett D, Bowen B, McCarthy P, Subramaniam A, O’Connor M, Henry MT. Outcomes of pulmonary rehabilitation for COPD in older patients: a comparative study. COPD. 2017;14(2):170–175. doi:10.1183/15412555.2016.1258051

19. Sant’Omil. Rapport mondial sur le vieillissement et la santé. Santé Omil, ed. 2016. Available from: https://apps.who.int/iris/bitstream/handle/10665/186469/WHO_FWC_ALC_15.01_fie.pdf?sequence=1. Accessed December 17, 2019.

20. Grosbois JM, Gicquello A, Langlois C, et al. Long-term evaluation of home-based pulmonary rehabilitation in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:2037–2044.

21. Grosbois JM, Heluin-Robiquet J, Machuron F, Chenivesse V, Wallaert B, Le Rouzic O. Influence of socioeconomic deprivation on short- and long-term outcomes of home-based pulmonary rehabilitation in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2019;14:2441–2449. doi:10.2147/COPD.S224348

22. Cavalleri V, Straker L,ucciardi DF, Gardiner PA, Hill K. Changing physical activity and sedentary behaviour in people with COPD. Respir Physiol. 2016;213(3):419–426. doi:10.1016/j.resp.2016.07.006

23. Hill K, Cavalleri V, Mathur S, et al. Neuromuscular electrostimulation for adults with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018;(5):CD018021.

24. Coquart JB, Grosbois JM, Olivier C, Bart F, Castres I, Wallaert B. Home-based neuromuscular electrical stimulation improves exercise tolerance and health-related quality of life in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:1189–1197. doi:10.2147/COPD.S105049

25. Borel B, Fabre C, Saison S, Bart F, Grosbois JM. An original field evaluation test for chronic obstructive pulmonary disease population: the six-minute stepper test. Clin Rehabil. 2010;24(1):82–93. doi:10.1177/0269215509343848

26. Lepine JP, Godchau M, Brun P. Anxiety and depression in inpatients. Lancet. 1985;2(8469–70):1425–1426. doi:10.1016/S0140-6736(85)92589-9

27. Perez T, Arnould B, Grosbois JM, et al. Validity, reliability, and responsiveness of a new short Visual Simplified Respiratory Questionnaire (VSQR) for health-related quality of life assessment in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2009;4:9–18.

28. Pichon R, Couturaud F, Mailon P, et al. Responsiveness and minimally important difference of the 6-minute stepper test in patients with chronic obstructive pulmonary disease. Respir Med. 2016;91(5):364–373. doi:10.1159/000446517

29. Beauchamp MK, O’Hoski S, Goldstein RS, Brooks D. Effect of pulmonary rehabilitation on balance in persons with chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2010;91(9):1460–1465. doi:10.1016/j.apmr.2010.06.021

30. Puhan MA, Frey M, Buchi S, Schumenn HJ. The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. Health Qual Life Outcomes. 2008;6:46. doi:10.1186/1477-7525-6-46

31. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8

32. Higashimoto Y, Yamagata T, Maeda K, et al. Influence of comorbidities on the efficacy of pulmonary rehabilitation in patients with chronic obstructive pulmonary disease. Geriatr Gerontol Int. 2016;16(8):934–941. doi:10.1111/ggi.12575

33. Bui K, Nyberg A, Malais F, Saey D. Functional Tests in COPD part 1: clinical relevance and links to the international classification of functioning, disability and health. Ann Am Thor Soc. 2017;14(5):778–784. doi:10.1513/AnnalsATS.201609-733AS
34. Dube BP, Laveneziana P. Effects of aging and comorbidities on nutritional status and muscle dysfunction in patients with COPD. J Thorac Dis. 2018;10(Suppl 12):S1355–S1366. doi:10.21037/jtd.2018.02.20
35. Hornikx M, Van Remoortel H, Demeyer H, et al. The influence of comorbidities on outcomes of pulmonary rehabilitation programs in patients with COPD: a systematic review. Biomed Res Int. 2013;2013:146148. doi:10.1155/2013/146148
36. Franssen FME, Rochester CL. Comorbidities in patients with COPD and pulmonary rehabilitation: do they matter? Eur Respir Rev. 2014;23:131–141. doi:10.1183/09059180.00076113
37. Effing TW, Verrouwen J, Bourbeau J, et al. Definition of a COPD self-management intervention: international expert group consensus. Eur Respir J. 2016;48(1):46–54. doi:10.1183/13993003.00025-2016
38. Liu XL, Tan YJ, Wang T, et al. Effectiveness of home-based pulmonary rehabilitation for patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials. Rehabil Nurs. 2014;39(1):36–59. doi:10.1002/rnj.112
39. Sundararajan L, Balam J, Packham S. Effectiveness of outpatient pulmonary rehabilitation in elderly patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil Prev. 2010;30(2):121–125. doi:10.1097/HCR.0b013e31813181be7c56
40. Sahin H, Varol Y, Naz I, Toksaval F. Effectiveness of pulmonary rehabilitation in COPD patients receiving long-term oxygen therapy. Clin Respir J. 2018;12(4):1439–1446. doi:10.1111/crj.12680
41. Roig M, Eng JJ, MacIntyre DL, et al. Falls in people with chronic obstructive pulmonary disease: an observational cohort study. Respir Med. 2011;105(3):461–469. doi:10.1016/j.rmed.2010.08.015
42. Panel on Prevention of Falls in Older Persons AGS, British Geriatrics S. Summary of the Updated American Geriatrics Society/British Geriatrics Society clinical practice guideline for prevention of falls in older persons. J Am Geriatr Soc. 2011;59(1):148–157. doi:10.1111/j.1532-5415.2010.03234.x
43. Reynaud V, Muti D, Pereira B, et al. A TUG value longer than 11 s predicts fall risk at 6-month in individuals with COPD. J Clin Med. 2019;8:10. doi:10.3390/jcm8101752
44. Troosters T, Gosselin R, Decramer M. Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Am J Med. 2000;109(3):207–212. doi:10.1016/S0002-9343(00)00472-1
45. Ries AL, Kaplan RM, Myers R, Prewitt LM. Maintenance after pulmonary rehabilitation in chronic lung disease: a randomized trial. Am J Respir Crit Care Med. 2003;167(6):880–888. doi:10.1164/rccm.200204-3180OC
46. Katsura H, Kanemaru A, Yamada K, Motogi T, Wakabayashi R, Kida K. Long-term effectiveness of an inpatient pulmonary rehabilitation program for elderly COPD patients: comparison between young-elderly and old-elderly groups. Respiriology. 2004;9(2):230–236. doi:10.1111/j.1440-1843.2004.00561.x
47. Spencer LM, McKeough ZJ. Maintaining the benefits following pulmonary rehabilitation: achievable or not? Respirology. 2019;24(9):909–915.
48. Roche N, Anzuo A, Bosnic Anticevich S, et al. The importance of real-life research in respiratory medicine: manifesto of the respiratory effectiveness group: endorsed by the International Primary Care Respiratory Group and the World Allergy Organization. Eur Respir J. 2019;54(3). doi:10.1183/13993003.01511-2019

---

**International Journal of Chronic Obstructive Pulmonary Disease**

**Publish your work in this journal**

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols. This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.